News and analysis on disease research and diagnostics.
In an interview, Marilyn Li and Douglas Stewart discuss why ACMG has put forth points that doctors and labs should consider when presumed germline findings crop up in tumor testing.
The firm has received a supplemental approval that provides its customers with an option to purchase its IVD-labeled FLT3 mutation assay for in-house testing.
Bristol Myers Squibb is hoping that the durable responses seen with the combined immunotherapy drugs will convince doctors to prescribe it for their patients.
One cohort will involve NSCLC patients with MET exon 14 skipping mutations, while two other cohorts will enroll patients with solid tumors with MET amplifications and fusions.
In a Phase I trial, non-small cell lung cancer patients with exon 20 insertions experienced durable responses with amivantamab.
